Key clinical point: Gene expression and DNA methylation patterns show association with treatment response to adalimumab and etanercept in rheumatoid arthritis.

Major finding: Machine learning models using different parameters predicted true-positive rates for response to adalimumab ranging from 76% to 90% and true-negative rates ranging from 70% to 89%, while for etanercept true-positive rates ranged from about 60% to 80% and true-negative rates ranged from about 82% to 98%.

Study details: A longitudinal, observational cohort study involving 80 patients with rheumatoid arthritis.

Disclosures: The study was supported by AbbVie, and two authors were supported by the China Scholarship Council and the Netherlands Organisation for Scientific Research. No conflicts of interest were declared.